Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Almirall/Forest: good PhIII in COPD; pivotal data soon

This article was originally published in Scrip

Executive Summary

Almirall and Forest Laboratories are gearing up to fight for a greater share of the crowded chronic obstructive pulmonary disease COPD market as they announced positive top-line Phase III data for a fixed dose combination (FDC) of a long-acting inhaled antimuscarinic agent (LAMA), aclidinium bromide and the long-acting beta-2-adrenergic agonist (LABA) formoterol fumarate. US and EU filings will take place following the completion of another trial, for which results are expected in the 'coming weeks'.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC021061

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel